JBIO short sellers made an aggressive move on May 7. Short interest jumped 33% in a single session to 9.2% of free float. The lending pool is now completely exhausted — availability has dropped to 0%, matching the 52-week tightest level.
Yet the options market tells a different story entirely.
The one-day surge was dramatic. Shares short rose from roughly 3.17 million to 4.23 million in 24 hours. Over the past month, short interest has risen 249%.
The lending market can't keep up. Availability has collapsed from around 130% on May 6 — when utilization sat at 68% — to 0% today. Every share in the lending pool is now out on loan. That happened in a single trading day.
Notably, the cost to borrow has been falling. CTB stands at 0.53%, down 40% week-on-week and more than 56% over the past month. That divergence — surging short interest alongside a falling borrow cost — suggests short sellers moved fast to lock in positions before the pool closed, rather than responding to a tightening squeeze.
The put/call ratio tells the opposite story. On May 6, the PCR collapsed to 1.02 — the 52-week low. The 20-day average sits at 4.49. That one-day reading is 2.9 standard deviations below the mean.
Call buying spiked sharply as short interest surged. The current PCR as of May 7 is back near the baseline at 4.96, but that one-session spike in call demand stands out. Something shifted in options positioning exactly as the borrow market closed off.
The catalyst sitting in the near term: earnings are scheduled for May 14.
Wall Street has been consistently bullish. HC Wainwright raised its price target to $45 on April 27 — up from $35. BTIG lifted its target to $39 in March. The mean price target across analysts is $30.14, against a current price of $24.22.
That implies roughly 24% upside to consensus — even after a 50% gain over the past month.
FMR (Fidelity) added 2 million shares in the most recent reported period, making it the largest institutional holder at nearly 14% of shares outstanding.
Three forces converge ahead of the May 14 print:
The borrow market is now shut. Any new short sellers will face friction. The data will come into focus when JADE201's Phase 1 trial progress features in the May 14 earnings update.
Data summary
See the live data behind this article on ORTEX.
Open JBIO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
